Drug Profile
Hydroxyprogesterone - Lipocine
Alternative Names: 17-alpha hydroxyprogesterone caproate; Hydroxyprogesterone caproate - Lipocine; Hydroxyprogesterone caproate oral - Lipocine; LPCN-1107; Oral hydroxyprogesterone caproate - LipocineLatest Information Update: 14 Aug 2022
Price :
$50
*
At a glance
- Originator Lipocine
- Class Hormones; Pregnenediones; Progesterone congeners; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Preterm labour
Highest Development Phases
- Phase II Preterm labour
Most Recent Events
- 08 Aug 2022 Hydroxyprogesterone - Lipocine is available for licensing as of 08 Aug 2022. https://www.lipocine.com/partnering/ 9365273
- 27 Jul 2021 Lipocine completes a phase II trial in Preterm labour (Prevention) (Lipocine website, July 2021)
- 05 Apr 2021 Hydroxyprogesterone caproate oral is still in phase II trials for Preterm labour (Prevention) in USA (PO) (Lipocine pipeline, April 2021)